These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19948206)

  • 1. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
    Pilarski LM; Belch AR
    Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
    Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
    Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.
    de Bont ES; Guikema JE; Scherpen F; Meeuwsen T; Kamps WA; Vellenga E; Bos NA
    Cancer Res; 2001 Oct; 61(20):7654-9. PubMed ID: 11606408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
    Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
    Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras.
    Ramírez M; Rottman GA; Shultz LD; Civin CI
    Exp Hematol; 1998 Apr; 26(4):332-44. PubMed ID: 9546317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice.
    Nitsche A; Junghahn I; Thulke S; Aumann J; Radonić A; Fichtner I; Siegert W
    Stem Cells; 2003; 21(2):236-44. PubMed ID: 12634420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice.
    Samira S; Ferrand C; Peled A; Nagler A; Tovbin Y; Ben-Hur H; Taylor N; Globerson A; Lapidot T
    Stem Cells; 2004; 22(6):1085-100. PubMed ID: 15536198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
    Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
    Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
    Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.